Literature DB >> 21208904

Frequent hSNF5/INI1 germline mutations in patients with rhabdoid tumor.

Franck Bourdeaut1, Delphine Lequin, Laurence Brugières, Stéphanie Reynaud, Christelle Dufour, François Doz, Nicolas André, Jean-Louis Stephan, Yves Pérel, Odile Oberlin, Daniel Orbach, Christophe Bergeron, Xavier Rialland, Paul Fréneaux, Dominique Ranchere, Dominique Figarella-Branger, Georges Audry, Stéphanie Puget, D Gareth Evans, Joan Carles Ferreres Pinas, Valeria Capra, Véronique Mosseri, Isabelle Coupier, Marion Gauthier-Villars, Gaëlle Pierron, Olivier Delattre.   

Abstract

PURPOSE: Germline hSNF5/INI1 mutations are responsible for hereditary cases of rhabdoid tumors (RT) that constitute the rhabdoid predisposition syndrome (RPS). Our study provides the first precise overview of the prevalence of RPS within a large cohort of RT. EXPERIMENTAL
DESIGN: hSNF5/INI1 coding exons were investigated by sequencing and by multiplex ligation-dependent probe amplification.
RESULTS: Seventy-four constitutional DNAs from 115 apparently sporadic RT were analyzed from 1999 to 2009. Germline mutations were found in 26 patients (35%). Data from 9 individuals from 5 RPS families (siblings) were also studied. The median age at diagnosis was much lower (6 months) in patients with germline mutation (P < 0.01) than in patients without (18 months). Nevertheless, 7 of 35 patients with germline mutation (20%) developed the disease after 2 years of age. The mutation could be detected in only 1 parent whereas germline blood DNA was wild type in the 20 other parent pairs, therefore indicating the very high proportion of germ-cell mosaicism or of de novo mutations in RPS. The former hypothesis could be clearly documented in 1 case in which prenatal diagnosis was positive in a new pregnancy. Finally, the 2 years' overall survival was 7% in mutated and 29% in wild-type patients, mainly due to the worse outcome of RT in younger patients.
CONCLUSIONS: Our results show a high proportion of germline mutations in patients with RT that can be found at any age and up to 60% in the youngest patients. Genetic counseling is recommended given the low but actual risk of familial recurrence. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21208904     DOI: 10.1158/1078-0432.CCR-10-1795

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  54 in total

Review 1.  Biology and Treatment of Rhabdoid Tumor.

Authors:  James I Geller; Jacquelyn J Roth; Jaclyn A Biegel
Journal:  Crit Rev Oncog       Date:  2015

2.  Reply to: Familial syndromes associated with intracranial tumours: a review.

Authors:  Fonnet E Bleeker
Journal:  Childs Nerv Syst       Date:  2015-08-09       Impact factor: 1.475

Review 3.  Germline variants in SMARCB1 and other members of the BAF chromatin-remodeling complex across human disease entities: a meta-analysis.

Authors:  Till Holsten; Susanne Bens; Florian Oyen; Karolina Nemes; Martin Hasselblatt; Uwe Kordes; Reiner Siebert; Michael C Frühwald; Reinhard Schneppenheim; Ulrich Schüller
Journal:  Eur J Hum Genet       Date:  2018-04-30       Impact factor: 4.246

4.  Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria.

Authors:  Scott R Plotkin; Jaishri O Blakeley; D Gareth Evans; C Oliver Hanemann; Theo J M Hulsebos; Kim Hunter-Schaedle; Ganjam V Kalpana; Bruce Korf; Ludwine Messiaen; Laura Papi; Nancy Ratner; Larry S Sherman; Miriam J Smith; Anat O Stemmer-Rachamimov; Jeremie Vitte; Marco Giovannini
Journal:  Am J Med Genet A       Date:  2013-02-07       Impact factor: 2.802

Review 5.  SWI/SNF chromatin remodeling complexes and cancer.

Authors:  Jaclyn A Biegel; Tracy M Busse; Bernard E Weissman
Journal:  Am J Med Genet C Semin Med Genet       Date:  2014-08-28       Impact factor: 3.908

6.  Malignant rhabdoid tumors originating within and outside the central nervous system are clinically and molecularly heterogeneous.

Authors:  Emilia M Pinto; Dima Hamideh; Armita Bahrami; Brent A Orr; Tong Lin; Stanley Pounds; Gerard P Zambetti; Alberto S Pappo; Amar Gajjar; Sameer Agnihotri; Alberto Broniscer
Journal:  Acta Neuropathol       Date:  2018-02-10       Impact factor: 17.088

7.  Atypical teratoid/rhabdoid tumor in the sella turcica of an elderly female with a distinct vascular pattern and genetic alterations.

Authors:  Sumihito Nobusawa; Satoshi Nakata; Junko Hirato; Takahiro Kawashima; Koji Sato; Hiroya Fujimaki; Naoki Okura; Hayato Ikota; Hideaki Yokoo
Journal:  Virchows Arch       Date:  2016-09-05       Impact factor: 4.064

Review 8.  Cancer Surveillance in Gorlin Syndrome and Rhabdoid Tumor Predisposition Syndrome.

Authors:  William D Foulkes; Junne Kamihara; D Gareth R Evans; Laurence Brugières; Franck Bourdeaut; Jan J Molenaar; Michael F Walsh; Garrett M Brodeur; Lisa Diller
Journal:  Clin Cancer Res       Date:  2017-06-15       Impact factor: 12.531

9.  Consistent SMARCB1 homozygous deletions in epithelioid sarcoma and in a subset of myoepithelial carcinomas can be reliably detected by FISH in archival material.

Authors:  Francois Le Loarer; Lei Zhang; Christopher D Fletcher; Agnes Ribeiro; Samuel Singer; Antoine Italiano; Agnes Neuville; Aurélie Houlier; Frederic Chibon; Jean-Michel Coindre; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2014-03-03       Impact factor: 5.006

10.  Long-term survival of an infant with an atypical teratoid/rhabdoid tumor following subtotal resection and low-cumulative dose chemotherapy: a case report.

Authors:  Viktor Arnhold; Florian Oyen; Reinhard Schneppenheim; Hannes Haberl; Arend Koch; Michael C Frühwald; Pablo Hernáiz Driever
Journal:  Childs Nerv Syst       Date:  2016-01-08       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.